Back to top

Image: Bigstock

Why You Shouldn't Bet Against Acushnet Holdings (GOLF) Stock

Read MoreHide Full Article

One stock that might be an intriguing choice for investors right now is Acushnet Holdings Corp. (GOLF - Free Report) . This is because this security in the Leisure and Recreation Products Sales space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Leisure and Recreation Products space as it currently has a Zacks Industry Rank of 30 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Acushnet Holdings is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Acushnet Holdings Corp. Price and Consensus

In fact, over the past month, current quarter estimates have risen from 54 cents per share to 58 cents per share, while current year estimates have risen from $1.37 per share to $1.55 per share. This has helped GOLF to earn a Zacks Rank #1 (Strong Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank stocks here.

So, if you are looking for a decent pick in a strong industry, consider Acushnet Holdings. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Acushnet (GOLF) - free report >>

Published in